Mepron
(Atovaquone)ApprovedSmall molecule
Atovaquone is an antiprotozoal medication used to treat and prevent a type of pneumonia called Pneumocystis jiroveci pneumonia (PCP) that commonly affects people with HIV. It works by stopping the growth of harmful organisms called protozoa that cause this infection.[2] Mepron is currently approved and in use across 12 indications[4].[1]
Mepron is one of 287 small molecule programs targeting Amebiasis. It is currently in Approved.
12
Indications
18
Total Trials
3
Active Trials
286
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Mepron
GGlaxo Dba Glaxosmithkline
Approved
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Navelbine
PPierre Fabre Medicament
Phase 3
Pyrotinib
HHengrui Therapeutics, Inc.
Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pneumonia5 trials
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
Not yet recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT07357103·416 enrolled
Bacterial Infections1 trial
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000811·690 enrolled
Children1 trial
Prophylaxis1 trial
9 more indications
Immunodeficiency1 trial
Encephalitis1 trial
Clinical Trial1 trial
Oral1 trial
Regulatory
FDA Approval Timeline[5]
Nov 25, 1992
MEPRON
NDA NDA020259
Feb 8, 1995
MEPRON
NDA NDA020500
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Mepron drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Atovaquone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Cytochrome B Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline